

## DELAWARE GROWTH & ECONOMIC IMPACT

**\$15.2M**  
TOTAL AWARDED  
TO PROJECTS  
THAT INCLUDED  
DELAWARE  
ORGS

**\$735K**  
MEMBERSHIP  
FEES  
SUBSIDIZED

**\$4.9M**  
AWARDED TO  
DELAWARE-LED  
PROJECTS

### Funding

**\$15.2M** awarded to projects that include Delaware organization participation

**\$4.9** awarded directly to projects led by Delaware organizations

NIIMBL has subsidized almost **\$735K** in membership fees for Delaware based academic institutions and small- to medium-sized businesses

**24**  
FUNDED  
PROJECTS

### Projects

Delaware organizations participated in **24** NIIMBL-funded projects

**100**  
STUDENTS  
SERVED

### Workforce

NIIMBL programs have introduced **100** students in Delaware to secure, well-paying, and high-need career pathways in the biopharmaceutical manufacturing industry

**12%**  
DELAWARE  
ORGS

**58%**  
S-M SIZED  
ORGS

### Companies

Delaware organizations represent **12%** of NIIMBL's national membership

**58%** are small- to medium-sized organizations with 500 employees or less

# DELAWARE HAS BECOME A NATIONAL LEADER IN BIOPHARMACEUTICAL MANUFACTURING INNOVATION.

NIIMBL is a consortium of industry, academic institutions, government agencies, and non-profit organizations working in collaboration to advance biopharmaceutical manufacturing innovation and workforce development in the United States.

## 25 Members In Delaware



### INVEST IN A PARTNERSHIP WITH NIIMBL

#### Chris Yochim

Director, Business Development  
[yochim@udel.edu](mailto:yochim@udel.edu)

#### Alok Patel

Assistant Director, Business Development, Strategic Initiatives  
[alok@udel.edu](mailto:alok@udel.edu)



Manufacturing is at the core of our industry. Our members' cutting-edge research and product development can only help patients when it is paired with sophisticated, state of the art production – at scale and to the highest regulatory standards... Biopharmaceuticals make up an expanding percentage of all new products in the industry pipeline. Manufacturing these products is a highly complex process – NIIMBL's proposed cGMP facility will step-change production technologies, reduce therapy costs and deliver a pipeline of Delawareans ready to fill the thousands of jobs the blooming industry will produce."

#### Michael Fleming,

President of Delaware BioScience Association